

Neola Medical expands leadership team with appointment of Director Disposable Product Development

Neola Medical AB (publ) is pleased to announce the appointment of Charlotta Lagerblad as Director Disposable Product Development, effective January 12, 2026, adding valuable strength to the leadership team within disposables – a key component of the company's revenue model.

With more than 15 years of experience in medical device at Atos Medical, Baxter and CellaVision, Charlotta Lagerblad brings extensive hands-on expertise in developing disposable medical products for daily clinical use and full-scale mass production. Her background includes responsibility for product development, design control, supplier collaboration and innovation projects across both EU and the U.S.

"Strengthening our leadership team with experience in scaling advanced disposables is of outmost strategic importance for Neola Medical as our disposables are a key driver for future recurring revenue streams. Charlotta Lagerblad brings deep experience in taking advanced disposable products from innovation into large scale manufacturing and global sales," says CEO Hanna Sjöström.

"What attracted me to Neola Medical is the company's strong focus on innovation with a clear path toward large-scale production. I look forward to contributing to the development of high-quality disposables that combine clinical performance with efficient manufacturing – an essential foundation for scalable growth," says Charlotta Lagerblad, incoming Director Disposable Product Development at Neola Medical.

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments

[Neola Medical expands leadership team with appointment of Director Disposable Product Development](#)